Red blood cell invasion by Plasmodium vivax: Structural basis for DBP engagement of DARC by Batchelor, Joseph D et al.




Red blood cell invasion by Plasmodium vivax:
Structural basis for DBP engagement of DARC
Joseph D. Batchelor
Washington University School of Medicine in St. Louis
Brian M. Malpede
Washington University School of Medicine in St. Louis
Natalie S. Omattage
Washington University School of Medicine in St. Louis
Gregory T. DeKoster
Washington University School of Medicine in St. Louis
Katherine A. Henzler-Wildman
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Batchelor, Joseph D.; Malpede, Brian M.; Omattage, Natalie S.; DeKoster, Gregory T.; Henzler-Wildman, Katherine A.; and Tolia,




Joseph D. Batchelor, Brian M. Malpede, Natalie S. Omattage, Gregory T. DeKoster, Katherine A. Henzler-
Wildman, and Niraj H. Tolia
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2583
Red Blood Cell Invasion by Plasmodium vivax: Structural
Basis for DBP Engagement of DARC
Joseph D. Batchelor1, Brian M. Malpede1, Natalie S. Omattage1, Gregory T. DeKoster2,
Katherine A. Henzler-Wildman2, Niraj H. Tolia1,2*
1Department of Molecular Microbiology and Microbial Pathogenesis, Washington University School of Medicine, Saint Louis, Missouri, United States of America,
2Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, United States of America
Abstract
Plasmodium parasites use specialized ligands which bind to red blood cell (RBC) receptors during invasion. Defining the
mechanism of receptor recognition is essential for the design of interventions against malaria. Here, we present the
structural basis for Duffy antigen (DARC) engagement by P. vivax Duffy binding protein (DBP). We used NMR to map the
core region of the DARC ectodomain contacted by the receptor binding domain of DBP (DBP-RII) and solved two distinct
crystal structures of DBP-RII bound to this core region of DARC. Isothermal titration calorimetry studies show these
structures are part of a multi-step binding pathway, and individual point mutations of residues contacting DARC result in a
complete loss of RBC binding by DBP-RII. Two DBP-RII molecules sandwich either one or two DARC ectodomains, creating
distinct heterotrimeric and heterotetrameric architectures. The DARC N-terminus forms an amphipathic helix upon DBP-RII
binding. The studies reveal a receptor binding pocket in DBP and critical contacts in DARC, reveal novel targets for
intervention, and suggest that targeting the critical DARC binding sites will lead to potent disruption of RBC engagement as
complex assembly is dependent on DARC binding. These results allow for models to examine inter-species infection
barriers, Plasmodium immune evasion mechanisms, P. knowlesi receptor-ligand specificity, and mechanisms of naturally
acquired P. vivax immunity. The step-wise binding model identifies a possible mechanism by which signaling pathways
could be activated during invasion. It is anticipated that the structural basis of DBP host-cell engagement will enable
development of rational therapeutics targeting this interaction.
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Introduction
Plasmodium vivax is a widely distributed human parasite, with
40% of the world’s population at risk of infection and an estimated
70–130 million cases of P. vivax malaria each year [1,2]. P. vivax is
prevalent in India, Southeast Asia, and South America [1], but is
rare in most of Sub-Saharan Africa [3]. This rarity is the result of a
silencing mutation in the Duffy blood group, found at frequencies
near fixation in Sub-Saharan Africa [4], that confers resistance to
P. vivax [5]. This phenotype has arisen independently at least three
times, and P. vivax in malaria endemic regions has driven selection
for the Duffy negative phenotype. This phenotype confers
protection against P. vivax because during red blood cell (RBC)
invasion the P. vivax Duffy Binding Protein (DBP) binds the Duffy
antigen/receptor for chemokines (DARC) on RBCs [6,7].
Therefore, RBCs which lack DARC are refractory to P. vivax
invasion. DARC is an atypical GPCR, thought to serve as a
‘reservoir’ for excess inflammatory chemokines [8].
Repeated cycles of RBC invasion and rupture cause the clinical
symptoms of malaria. To invade a RBC, Plasmodium merozoites
release the contents of specialized apical organelles: the micro-
nemes and rhoptries. DBP is a member of the erythrocyte binding-
like (EBL) family of proteins, which localize to micronemes and
use Duffy binding-like (DBL) domains to bind specific RBC
receptors with high affinity. DBL domains are located in ‘‘region
II’’ of EBL proteins [9,10], and DBP region II (DBP-RII) is
required for formation of a tight junction between Plasmodium and
RBC membranes. DBP is an exceptional P. vivax therapeutic target
because it is the sole EBL family member in the P. vivax genome
[11]. This contrasts with P. falciparum, which has multiple,
redundant EBL family members which mediate RBC invasion
by binding different host RBC receptors.
DBP is a leading vaccine candidate against P. vivax malaria [12].
Individuals living in endemic regions develop natural immunity to
P. vivax in an age-dependent manner which strongly correlates
with humoral and cellular recognition of DBP-RII [13–15].
Antibodies against DBP inhibit P. vivax RBC invasion [16], and
antibody epitopes in DBP-RII recognized by inhibitory antibodies
have been identified [17]. However, due to a high level of
polymorphism in DBP-RII and the selection for strain-specific
immunity, identifying residues that are essential to the invasion
interaction is still a critical step towards defining vaccination
targets.
Previous studies have illuminated key determinants of DBP-RII
binding to DARC and begun to define essential elements of the
binding interaction. DARC exists as two codominant alleles, Fya
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and Fyb, with a single polymorphism at residue 42. Fya contains a
glycine, and Fyb an aspartate (G/D42) at this position. The Fyb
phenotype has been shown to increase binding to DBP-RII [18]. It
is also known that recombinant DARC is sulfated at tyrosine
residues 30 and 41, and sulfation of tyrosine 41 has been shown to
play a role in binding to DBP [19]. Specifically, a sulfated
recombinant DARC N-terminus construct inhibits the DBP-RII
erythrocyte interaction to a greater extent than an unsulfated
construct. Extensive functional studies have also suggested
interaction residues for both DBP-RII and DARC [20–25]. The
crystal structure of DBP-RII has been solved [26], and illuminated
a putative sulfotyrosine binding pocket. Biophysical studies have
demonstrated that a non-sulfated DARC construct functionally
binds and is capable of inducing dimerization of DBP-RII [26],
suggesting that regions outside of the sulfotyrosine residues play an
important role in the binding interaction. Despite these studies on
the DBP-RII interaction with DARC, the full mechanism of
binding and complete extent of molecular interactions between
these binding partners are not fully understood.
In an effort to define the mechanism of DBP red blood cell
binding and to identify specific molecular interactions at the P.
vivax invasion interface, DBP-RII was crystallized with the DARC
ectodomain. Two crystal forms were observed, a heterotrimeric
complex in which one DARC molecule binds the DBP-RII dimer,
and a heterotetrameric complex containing two DARC molecules
bound to the DBP-RII dimer. The crystal structures of these two
complexes represent the first structural characterization of a
receptor-bound Plasmodium EBL ligand and provide insight into
the structure of a portion of the DARC ectodomain that mediates
this interaction. The structures illuminate DARC contact residues
that explain inter-species barriers to P. vivax infection. In addition,
point mutations in DARC binding site residues within P. knowlesi
DBP homologs provide a potential model for the molecular basis
of receptor specificity within the EBL family. The heterotetrameric
complex shows that the DARC molecules are bound in parallel,
resulting in a Plasmodium proximal face and a RBC proximal face
of DBP-RII. The structures confirm the previously identified DBP-
RII dimer interface [26] as a putative target of protective
immunity, and reveal novel targets for naturally acquired
immunity, including the RBC proximal face of DBP-RII and
the DARC-binding pockets. Our studies also provide the basis for
a framework defining the mechanism of DARC engagement by P.
vivax. Specifically, the two bound forms of DBP-RII observed in
the crystal structures suggest that an initial binding event followed
by receptor-induced DBP dimerization leads to a DBP:DARC
heterotrimer that subsequently binds to a second DARC monomer
to create the final heterotetrameric assembly. Isothermal titration
calorimetry (ITC) experiments performed with recombinant
DARC and DBP-RII support the two state, induced dimerization
model of erythrocyte engagement.
Results
DBP-RII engages the central region of the DARC N-
terminal ectodomain
DARC binds DBP-RII through its N-terminal 60 amino acid
ectodomain [7] and DARC binding induces dimerization of
DBP-RII [26]. Binding and dimer-induction in vitro has been
demonstrated for non-tyrosine sulfated DARC N-terminal ecto-
domain with three cysteines mutated to alanine [26]. These
cysteines in DARC are thus unlikely to be necessary for the
interaction with DBP-RII but appear to be important to the
recognition of chemokines, suggesting that disulfide linkages may
be important for the folding of native DARC [27]. NMR
experiments were performed to determine the region of an
unsulfated version of the DARC N-terminal ectodomain contacted
by DBP-RII (Fig. 1). Resonance assignments for the 60 N-terminal
amino acids of DARC (DARC 1–60) were obtained by standard
triple resonance experiments. The peaks are not well dispersed
(Fig. 1) and chemical shifts closely match canonical random coil
chemical shifts, consistent with a lack of secondary structure.
In the presence of DBP-RII, the large size of the 88 kDa DBP-
RII:DARC1–60 complex led to significant broadening of many
peaks, preventing full assignment. However, comparison of the
spectra between bound and unbound states revealed that signals
corresponding to the first N-terminal 15–16 amino acids overlay
well and have only modest line broadening. This result suggests
that this region remained unstructured upon binding and does not
directly contact DBP-RII. At the C-terminus, residues from 44–60
exhibit some line broadening or chemical shift changes, but this
region, similar to that of the N-terminus, was still relatively
unperturbed upon binding to DBP-RII. In contrast, peaks
corresponding to the central region of DARC1–60 became
significantly broadened, shifted, or disappeared in the bound
complex. These results indicate that residues within the central
region of the DARC ectodomain are highly perturbed upon
interaction with DBP-RII and are thus most likely to directly
contact DBP and form the minimal binding domain. This result is
consistent with a region from DARC sufficient for blocking RBC
binding by DBP-RII [22].
The DARC ectodomain forms a helix that binds the dimer
interface of DBP-RII
Screening for crystallization conditions of DBP-RII in complex
with DARC ectodomain constructs designed around the central
binding region resulted in two crystal structures of the DBP-
RII:DARC complex. The first was a 1.95 A˚ crystal structure of a
2:1 complex of DBP-RII:DARC16–43 (Table 1). In this structure,
two DBP-RIIs (DBP1 and DBP2) bind a single DARC (DARC A)
creating the heterotrimer (Fig. 2A) with a total buried surface area
of 2241.8 A˚2. The second structure was a 2:2 complex of DBP-
RII:DARC14–43 that was refined to 2.6 A˚ (Table 1). In the
second structure, two DBP-RIIs each bind two DARCs (DARC A
and DARC B) creating two DARC binding sites. This architecture
creates a heterotetramer (Fig. 2B), with a total buried surface area
Author Summary
Malaria parasites, including Plasmodium vivax, must
actively invade erythrocytes during blood stage growth
in humans. P. vivax Duffy Binding Protein (DBP) is a critical
invasion ligand that recognizes the receptor Duffy antigen/
Receptor for chemokines (DARC) during invasion. To
identify critical binding contacts during parasite red blood
cell invasion and determine the molecular basis of DBP
receptor recognition, we identified the minimal region of
DARC contacted by DBP and performed structural studies
on the minimal binding domain of DBP in complex with
the minimal region from DARC. These studies revealed that
two DBP molecules bind two DARC molecules. We
performed erythrocyte binding assays with binding site
mutants and identified essential receptor contacts. The
identification of receptor binding sites and molecular
interactions critical to the invasion process provides a basis
for targeted disruption of erythrocyte invasion mediated
by DBP. The structural and functional studies of DBP and
DARC presented here may aid in the rational design of
vaccines and invasion inhibitory therapeutics.
DBP Engagement of DARC
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of 3628.6 A˚2. We postulated that the two structures represent
snapshots in the assembly of the DBP-RII:DARC complex and
may define structural changes during step-wise binding. Addition-
ally, in the heterotrimer, the second DARC binding site is
preformed to accept another DARC. In both crystal forms the two
DBP-RII molecules are not identical and no higher order symmetry
exists in the asymmetric unit. Therefore, DARC binding results in
two distinct DBP-RII molecules in each asymmetric unit.
DBP-RII interacts with DARC in a step-wise binding
process
We utilized ITC to examine the mechanism of DBP-RII:DARC
engagement and assembly in solution. ITC is an excellent
technique to unambiguously determine interaction stoichiometries
and can be applied to examine step-wise and multi-state binding
systems in solution. Titration of DARC1–60 into DBP-RII
demonstrated that DARC binding occurs in a step wise assembly
consistent with the crystallographic studies. A biphasic binding
isotherm indicative of a two-state assembly was observed (Fig. 3).
The first binding event has a molar ratio of 0.5, expressed in
monomers of DBP-RII, indicative of a 2:1 heterotrimeric complex
of (DBP-RII)2:(DARC1–60)1. The second binding event occurs at
a molar ratio of 1 indicative of a 2:2 heterotetrameric complex or
(DBP-RII)2:(DARC1–60)2. The data were fit to a two independent
site binding model which suggested affinities of 21816125 nM for
the first binding event and 88.5626.6 nM for the second binding
event, consistent with high affinity binding. However, it should be
noted that the two independent site binding model is not a perfect
description of DBP-RII:DARC binding as receptor-induced
dimerization is not included in the model. Therefore, exact
affinity determination will require further work necessary to define
all thermodynamic parameters of binding. While the exact affinity
will require a more detailed fitting model, the stoichiometries
determined and thus the observation of step-wise assembly in
solution are not affected by the fitting model selected and are
reliable. In summary, the crystallographic and ITC solution data
presented here demonstrate a multi-step sequential binding
mechanism involving DARC-induced assembly of DBP-RII.
Identification of molecular interactions between DARC
and DBP-RII
The NMR studies indicate DARC1–60 lacking three cysteines
is unstructured in the absence of DBP-RII. In both structures,
clear density is seen for DARC residues 19–30 (Fig. S1). DARC is
induced to form an amphipathic helix in the crystal structures
upon binding and engages a positively charged groove at the DBP-
RII dimer interface (Fig. S1). All DARC interacting residues and
the dimer interface of DBP-RII are located in subdomain 2 of
DBP-RII. In addition to the dimer interface, each DARC binding
site, one in the heterotrimer and two in the heterotetramer, can be
broken into two interfaces: a primary DARC binding interface
with one DBP-RII monomer, and a secondary DARC binding
interface created by the second DBP-RII monomer (Fig. 4 and 5,
Table 2 and 3). The DBP-RII homodimer interface is composed of
DBP1 residues I265-R274 and DBP2 residues F261-Y278 in the
heterotrimer (Fig. 4C), and DBP1 residues H262-R274 and DBP2
residues F261-Y278 in the heterotetramer (Fig. 5B). The primary
DARC binding interface in both structures consists of DBP-RII
residues L270-K289 of helix 4 and Q356-K367 of helix 7 (Fig. 4
and 5). DBP-RII binds the amphipathic DARC helices through a
hydrophobic core flanked by electrostatic interactions.
The secondary DARC binding interface is formed by residues
V254 to F267 (loop 254–267) (Fig. 4B, 5C–D). When DBP-RII is
not bound to DARC this region is disordered [26]. Loop 254–267
contains residues which are required for binding [20], and are
recognized by neutralizing antibodies [17]. When DARC is
bound, loop 254–267 becomes ordered and engages the DARC
bound by the primary interface of a neighboring DBP-RII. In
the heterotrimer, residues H262-T266 make contacts at the
secondary interface (Fig. 4B). In the heterotetramer, DBP1
residues R263-I265 and DBP2 residues F261-D264 contact
DARC of the opposing monomer (Fig. 5C–D). Thus, DARC is
sandwiched between two DBP-RII molecules in each DARC
binding site.
Architectural transitions upon receptor binding
In the absence of receptor, DBP-RII crystallized as a dimer
stabilized by phosphates [26]. Although this prior structure
resembles the receptor-bound conformation presented here, there
are substantial structural differences in the architecture of the
dimer compared to the heterotrimer or heterotetramer. These
differences are crucial towards correctly defining the invasion
interaction. In the heterotrimer structure, a new DBP-RII
homodimer interface is created by a translation of 7 residues
covering 12 A˚ along helix 4, relative to the unbound structure (Fig.
S2A). The heterotetramer structure has a larger translation along
the same interface in the same direction, with a second 12 A˚
displacement relative to the heterotrimer (Fig. S2B), and a 23 A˚
displacement relative to the unbound DBP-RII homodimer
Figure 1. Residues 14–43 of DARC contain the minimal binding
region. 1H-15N-TROSY spectra of unbound DARC 1–60 (black) overlaid
on 1H-15N-TROSY spectra of DARC 1–60 in the presence of excess
unlabelled DBP-RII (red). Sequence assignments are shown for the
unbound DARC 1H-15N-TROSY spectra. Peaks still visible in the presence
of DBP-RII (red) are at DARC 1–60’s N- and C- termini. Residues that
disappear in the presence of DBP-RII are in the center of DARC and
delineate the binding region.
doi:10.1371/journal.ppat.1003869.g001
DBP Engagement of DARC
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interface (Fig. S2C). The directionality of these transitions is
consistent with sequential steps in a stepwise mechanism of
receptor binding. While there are major changes in the
DBP-RII:DARC complex architectures, individually each DBL
domain aligns well to the DBP-RII DBLs solved in the absence of
receptor (Fig. S2D–G).
Table 1. Data collection and refinement statistics.
DBP-RII:DARC heterotrimer DBP-RII:DARC heterotetramer
Data collection
Space group P2(1) P1
Cell dimensions
a, b, c (A˚) 59.59, 66.99, 97.92 37.39, 59.47, 91.67
a, b, c (u) 90, 102.112, 90 103.143, 91.098, 100.241
Resolution (A˚)* 20-1.95 (2.0-1.95) 20-2.6 (2.7-2.6)
Rsym
* .098 (1.01) 0.052 (0.538)
I/sI* 14.54 (2.11) 12.32 (1.69)
Completeness (%)* 99.8 (99.7) 95.2 (93.1)
Redundancy* 7.96 (7.96) 2.4 (2.2)
Refinement
Resolution (A˚) 20-1.95 20-2.6 A˚











Bond lengths (A˚) 0.003 0.002
Bond angles (u) 0.743 0.543
*Values in parentheses are for highest-resolution shell.
Data were collected on a single crystal for each dataset.
doi:10.1371/journal.ppat.1003869.t001
Figure 2. Crystal Structure of the DBP-RII:DARC heterotrimer and heterotetramer. Overview of (A) DBP-RII:DARC heterotrimer and (B) the
DBP-RII:DARC heterotetramer. Rotated views, (C) and (D), show DARC helices are oriented in parallel in the heterotetramer. DBP-RII monomers are in
yellow and green. DARC monomers are in purple and blue.
doi:10.1371/journal.ppat.1003869.g002
DBP Engagement of DARC
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Critical contacts in DARC
The observation that DARC 19–30 is contacted by DBP-RII is
consistent with alanine scanning work [23]. Mutation of DARC
residues 20–22 and 24–26 abrogated binding in a direct protein
interaction assay. Each of these residues, with the exception of D21,
makes direct contacts with DBP-RII and are buried in the complex
(Fig. 4 and 5). D21, which is required for DBP-RII binding but does
not directly contact DBP-RII, stabilizes the DARC N-terminal helix
dipole by positioning its acidic side chain directly over the helix.
E23, on the other hand, is on the surface of the complex and is
solvent exposed. Mutation of E23 to alanine had no effect on
binding consistent with its location in the complex.
Sulfotyrosine residues in DARC increase DARC’s ability to
inhibit DBP-RII RBC binding [19]. A previous structure of DBP-
RII alone identified a potential sulfotyrosine binding site that
includes residues K273 and Q356 [26]. In the receptor-bound
structure presented here, the hydroxyl of DARC Y30 points
directly at this pocket created by K273, and Q356 (Fig. S3).
Therefore, sulfotyrosine 30 appears to bind at this site when
DARC is sulfated. DARC residues 14–43 were included in our
crystallographic studies. However, clear density was only observed
for residues Q19 to Y30, and no density was present for the
remainder of DARC. The crystallographic data along with the
RBC binding studies discussed above support that residues 19–30
constitute a critical interaction site with DBP-RII.
Residues in DBP-RII that contact DARC are required for
RBC engagement
Having identified residues of DBP-RII that directly contact
DARC, structure-guided mutagenesis was used to determine
whether this model of binding explains DBP engagement of RBCs
(Fig. 6). Mutation of residues Y363 or A281 in the primary DARC
binding interface led to a complete loss of binding in a functional
RBC binding assay. This is expected as DARC binding drives
complex formation and mutations preventing DARC binding will
completely abrogate complex formation and attachment. These
results are consistent with previous mutational studies that
identified potential interaction residues between DBP-RII and
DARC [20,21], several of which map to the interaction surfaces
identified here. Residues D264, I265 and T266 are located in the
secondary DARC binding interface and directly contact DARC.
Mutation of these residues resulted in a loss in RBC binding,
demonstrating that the secondary DARC binding interface plays a
role in engaging DARC during RBC invasion. Large bulky amino
acid changes are required in order to disrupt binding by mutation
at the secondary binding site, as is expected from the large contact
area created by the additional interfaces in the full complex. The
need for large changes is consistent with a lack of an effect on
binding when mutations to alanine or conservative changes were
introduced at these residues [20,28]. Together, these results
support the functional role of both DARC binding interfaces.
DARC on erythrocytes is putatively sulfated [19]. The mutational
studies discussed above show that sulfation of DARC on erythrocytes,
and the remaining segments of full length DARC, cannot compensate
for the loss of the critical binding sites containing L270-K289 and
Q356-K367 that bind DARC 19–30. In particular, recombinant
DBP-RII containing Y363A is unable to bind to sulfated DARC in
vitro [21]. This result also demonstrates that sulfation of DARC
cannot compensate for the loss of the DARC binding sites induced by
the Y363A mutation. Together, the results identify essential binding
residues within DBP-RII, consistent with prior studies, which form
critical binding sites required for engagement of DARC.
DBP receptor specificity is manifested through changes
in the DARC binding sites
P. knowlesi uses three different DBP homologs to invade human
and rhesus macaque RBCs [10]. Only P. knowlesi DBPa (PkDBPa)
binds DARC, while PkDBPb and PkDBPc do not bind human
RBCs and recognize a receptor other than DARC [10]. This
receptor specificity is likely due to three amino acid changes in the
Figure 3. Isothermal titration calorimetry reveals step-wise binding of DARC to DBP-RII in solution. (A) A biphasic binding profile is
observed indicating the formation of the heterotrimer at a molar ratio of 0.5 (n1 = 0.4460.02, Kd1 = 21836125 nM, DH1 =22663669 cal/mol) and
heterotetramer at a molar ratio of 1 (n2 = 0.5060.02, Kd2 = 88.5626.6 nM, DH2 =23338623 cal/mol). The fit to the two independent site binding
model is shown as a red line. Molar ratios are expressed as monomers of DBP-RII. Open circles denote unbound DBP, closed circles denote bound
DBP. Titration of (B) PBS into DBP and (C) DARC into PBS reveals no observable profiles demonstrating the biphasic profile is due to DARC binding to
DBP. In all cases, the top panel contains raw binding data, and the bottom panel changes in enthalpy associated with binding.
doi:10.1371/journal.ppat.1003869.g003
DBP Engagement of DARC
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critical DARC binding site of DBP that are changed to non-
conservative amino acids in PkDBPb and/or PkDBPc (Fig. 6C).
The DBP residue with the most extensive DARC contacts is Y363.
In both PkDBPb and PkDBPc, Y363 is changed to leucine.
Mutation of Y363L resulted in a complete loss of binding (Fig. 6D
and E) consistent with a role for this residue in receptor specificity.
Additionally, R274E and Q356Y in PkDBPb, as well as Q356D in
PkDBPc, would likely destabilize DARC binding as both R274
and Q356 contact the DARC residues E23 and Y30, respectively.
It has been demonstrated that a R274E mutation in DBP-RII
completely prevents RBC binding [26]. Mutation of Q356D and
Q356Y resulted in a loss in RBC binding, with Q356D having a
large effect (Fig. 6D and E). Thus, contacts identified in the
DBP:DARC structure provide insight into why PkDBPb or
PkDBPc do not bind DARC on human RBCs.
Discussion
Numerous functional and immunological studies have been
conducted on the P. vivax DBP invasion system since the Duffy
antigen was found to be essential to this species in the 1970’s [5].
Here we have shown using crystallography that DBP-RII binds
DARC forming a heterotrimer and heterotetramer and demon-
strated using ITC that the interaction assembles in discrete steps.
In addition, we identify DARC residues 19–30 as a critical
interaction site for DBP-RII binding, and thus to tight junction
formation during invasion. These studies also identify DBP-RII
residues that directly contact the DARC receptor, including L270-
K289, Q356-K367 and F261-T266. The structural and mecha-
nistic basis of Duffy recognition by P. vivax provides a context for
prior work and may assist with the rational design of therapeutics
and vaccines targeting this essential P. vivax binding interaction.
Phylogenetic studies have identified primate DARC residues
under positive selection to block Plasmodium infection [29]. V25 in
DARC is especially polymorphic among primates and under
strong positive selection. This is because DBP makes essential
hydrophobic packing interactions with V25 (Fig. 7A), disruption of
which would strongly destabilize binding. Gorillas, the ancient
host of P. falciparum [30], have a V25A mutation in DARC. This
disrupts hydrophobic interactions, prevents DBP binding [23], and
serves as an inter-species barrier to P. vivax infection.
Figure 4. Binding interfaces of the DBP-RII:DARC heterotrimer. (A) Global view of the DBP-RII:DARC heterotrimer, showing (B) DARC
monomer A interactions and (C) the DBP-RII homodimeric interface. DARC monomer A is in purple, DBP-RII monomer 1 is in green and DBP-RII
monomer 2 is in yellow. Residue numbers are labeled and DARC residue labels are underlined.
doi:10.1371/journal.ppat.1003869.g004
DBP Engagement of DARC
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Figure 5. Binding interfaces of the DBP-RII:DARC heterotetramer. (A) Global view of the DBP-RII:DARC heterotetramer, showing (B) the DBP-
RII homodimeric interface, (C) DARC monomer A interactions, and (D) DARC monomer B interactions. DARC monomer A is in purple, DARC monomer
B is in blue, DBP-RII monomer 1 is in green and DBP-RII monomer 2 is in yellow. Residue numbers are labeled and DARC residue labels are underlined.
doi:10.1371/journal.ppat.1003869.g005
Table 2. Heterotrimer interface residues determined by PDBePISA [47]: All residues in the interface are listed sequentially and do
not indicate interacting pairs.
DARC binding site Dimer Interface
Primary DARC binding interface (DARC A to DBP
1)
Secondary DARC binding interface (DARC A to
DBP2)
DARC A DBP 1 DARC A DBP 2 DBP 1 DBP 2
GLN19 LEU270 PHE22 HIS262 PHE261 ILE265
LEU20 LYS273 GLU23 ARG263 HIS262 THR266
ASP21 ARG274 TRP26 ASP264 ASP264 PHE267
PHE22 ILE277 ASN27 ILE265 LEU270 LEU270
ASP24 TYR278 TYR30 THR266 TYR271 TYR271
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Sequencing of parasite populations show particular sites of DBP
are under strong positive selective pressure to evade the immune
response [31–33]. Many polymorphic DBP residues are located far
from the DARC binding sites (Fig. 7B) [20,21]. The most
polymorphic region of DBP, the DEK epitope, forms a ridge
directly opposite DARC, flanking the secondary binding interface
and homodimer interface. Converting this epitope to small,
nonpolar amino acids, focuses the immune response towards
cross-specific neutralizing epitopes [34]. Our results suggest that
this hypervariant DEK epitope does not play a direct role in
DARC binding. Polymorphisms in the DEK epitope should not
affect DBP function, but could interfere with immune recognition
of DBP. Antibody recognition of the hypervariant DEK epitope
may neutralize P. vivax by preventing assembly of the DBP-
RII:DARC complex, and thus sterically preventing DBP-RII
homodimeric contacts. Polymorphisms are heavily selected for
within the DEK epitope suggesting P. vivax evades this potentially
neutralizing antibody response by antigenic variation within these
residues.
The studies presented here define a putative mechanism for
known neutralizing epitopes of P. vivax DBP-RII and illuminate
potential new targets for naturally acquired immunity. Specifically,
both DARC helices are oriented in a parallel manner (Fig. 2B and
2D), and DARC itself is a homodimeric GPCR. Because only 30
amino acids, DARC residues G31 to S60, separate the structure
from the RBC membrane, the surface of the DBP-RII dimer with
DARC Y30 is proximal to the RBC membrane, and the alternate
surface faces the Plasmodium membrane. Antibody recognition of
DBP-RII’s RBC proximal surface prior to DARC binding
neutralizes DBP by sterically preventing DBP-RII from approach-
ing the RBC surface. This model is confirmed by recent work
which identified several DBP neutralizing epitopes recognized by
human antibodies from individuals living in endemic areas [17]
which are located either directly at the DARC binding sites or at
DBP-RII’s RBC proximal surface (Fig. 7C). In addition, the most
potent known neutralizing epitope for DBP includes much of helix
4 and loop 254–267 [17], which contains the DBP-RII dimeriza-
tion interface and the DARC binding sites. Disrupting DBP-RII
dimerization would both destabilize DARC binding by preventing
secondary DBP-RII contacts and destroying interaction contribu-
tions due to avidity. Recently, mouse monoclonal antibodies that
bound subdomain 3 of DBP-RII also blocked binding to
erythrocytes [35]. Subdomain 3 lies in close proximity to the
RBC surface (Fig. 8) and these antibodies may block binding by
preventing DBP-RII from approaching the RBC surface and
contacting DARC. The identification of two DARC binding sites
Figure 6. The structural studies define red blood cell binding. (A) Adherent HEK293 cells in grey bind to darker, smaller red blood cells when
transfected with a DBP-RII surface expression plasmid with a GFP marker. Red blood cell rosetting images for DBP-RII mutants, showing bright field
(left), GFP (center), and merged images (right). (B) Percentage of cells expressing point mutants which bind red blood cells, relative to wildtype,
shown with standard error. (C) The major DBP-RII:DARC residues identified in the crystal structures are indicated by red dots. Non-conservative P.
knowlesi mutations at critical DBP-RII:DARC contact residues 274, 356, and 363 suggest why PkDBPa but not PkDBPb or PkDBPc bind DARC. (D) Red
blood cell rosetting images for DBP-RII receptor specificity mutants, showing bright field (left), GFP (center), and merged images (right). (E)
Percentage of cells expressing receptor specificity point mutants which bind red blood cells, relative to wildtype, shown with standard error.
doi:10.1371/journal.ppat.1003869.g006
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within DBP-RII and the structural orientation of each molecule
provide insight into the mechanisms of antibody inhibition of P.
vivax RBC invasion. It appears that antibodies targeting DBP-RII
are capable of preventing DARC binding by recognizing DBP-
RII’s RBC proximal surface, DARC recognition sites, or the
homodimeric interface, and may block invasion using other,
currently unidentified mechanisms.
The crystallographic and ITC solution studies presented here
support a step-wise binding model in which receptor-induced
DBP-RII dimerization facilitates formation of a heterotrimer that
subsequently recruits a second DARC molecule to form a
heterotetramer (Fig. 8). Due to avidity contributions to binding
inherent in a two-site mechanism, this heterotetrameric complex
may enable the observed tight binding of P. vivax to the RBC
membrane. Since recombinant DBP-RII is monomeric in the
absence of DARC when examined in solution [26], the dimer
interface and DARC binding pockets are exposed and accessible
to antibodies prior to DARC engagement. DARC is known to
exist as a homodimeric and heterodimeric GPCR [36]. The
heterotrimer and heterotetramer could represent DBP-RII bind-
ing to a DARC heterodimer or homodimer, respectively. The
observed transitions may be a selectivity mechanism for DBP-RII
to preferentially bind homodimeric DARC while maintaining the
ability to bind to a DARC heterodimer. The binding model
proposed here is applicable to other DBL domain proteins that
may oligomerize upon receptor binding [9,26,37–39]. Since
dimerization is prevalent in receptor signaling, it is plausible that
complex assembly initiates a signal through the transmembrane
and cytoplasmic domains of DBP to activate pathways of invasion.
Although structure determination of the DBP-RII:DARC
complexes allows for visualization and identification of critical
contact points, the relevance of each intermediate to complex
assembly in solution is not immediately known from the static
pictures of binding. To begin to assess the biological role of
complex assembly, we utilized ITC to demonstrate that two
binding events corresponding to the formation of a heterotrimer
and heterotetramer exist in solution. We further tested mutant
DBP-RII constructs for RBC binding and demonstrated that these
mutations ablate binding to RBCs, supporting the biological role
of the DARC contacts identified here as well as the role of the
dimer interface. In addition, the large buried surface area for both
DARC binding sites and the ITC measurements suggest high
affinity interactions. This study thus unambiguously identifies
DARC residues 19–30 as a critical binding element that interacts
with DBP residues L270-K289, Q356-K367 and F261-T266.
The biphasic profile obtained by ITC is different from studies
previously reported where a single binding event with a molar
ratio of 1 was observed indicative of the heterotetramer [26]. This
difference is likely due to the buffer conditions used in each case.
In prior studies, titrations were performed at a salt concentration
of 50 mM while the studies presented here were performed in PBS
to examine binding under physiological conditions. These results
suggest that observation of the heterotrimer intermediary step by
ITC is salt dependent. Never-the-less, the biphasic profile and step
wise binding mechanism presented here are representative of the
assembly mechanism under physiologically relevant conditions.
Figure 7. Mapping polymorphic residues and inhibitory
epitopes reveals targets of selective pressure. DBP-RII molecules
are in green and yellow. DARC molecules are in purple and blue. DARC
residue labels are underlined. (A) Nonsynonymous DARC polymor-
phisms in primates, residues colored in blue, which make critical
contacts with DBP-RII provide a mechanism for inter-species transmis-
sion barriers. (B) Polymorphic DBP residues, in blue, are spread
throughout the molecule. The most polymorphic region of DBP is the
‘‘DEK epitope’’ opposite the DARC14–43 binding site. (C) Inhibitory
epitopes, in red and brown, map to the heterotetramer interface, DARC
binding pockets and RBC proximal face of DBP-RII.
doi:10.1371/journal.ppat.1003869.g007
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In both crystal structures, clear electron density was observed
for residues 19–30 of DARC. The binding pockets in DBP
identified here are distinct from a patch of residues previously
suggested to engage DARC [40] (Fig. S4). These residues were
proposed based on loss of binding of DBP to DARC upon
mutation; however, no data for direct interaction of this patch of
residues with DARC was presented. In contrast, the crystal
structure of P. vivax DBP in complex with DARC demonstrates
clear contact points between the two binding partners, and
mutagenesis data strongly supports the critical role of the residues
identified in the binding pockets.
Mutational studies [20,21] and glycan shielding experiments
[28] have identified several patches of residues that affect binding
of DBP to RBCs, some of which overlap and are consistent with
the DARC contacts identified here. There are additional residues
outside the DARC binding pockets that when altered reduce
binding [20,21,28]. Therefore, the complete range of interactions
between DARC and DBP-RII will likely include additional
patches of residues in DBP. Specifically, sulfation of tyrosine 41
and the Fya/Fyb polymorphism have been shown to play a role in
binding [18,19]. However, the specific mechanism by which these
changes impact binding is unknown. In addition, an association
between the N-terminus and additional extracellular loops of
DARC has been suggested to play a role in chemokine binding to
DARC [27]. Further studies are necessary to fully understand the
role of tyrosine sulfation, the Fya/Fyb polymorphism, and the
potential role of additional regions and loops of DARC during P.
vivax binding and RBC invasion.
The identification of critical DARC binding pockets presented
in this study may facilitate the rational design of therapeutics that
seek to inhibit RBC binding. Small molecule inhibitors that bind
to the DARC binding pocket and prevent DARC engagement
could disrupt merozoite invasion, and thus P. vivax growth.
Alternately, disruption of complex assembly by small molecules, as
has been described for AMA-1:RON-2 [41], or antibodies would
also provide novel methods for preventing RBC invasion. Since
complex assembly is dependent on DARC binding, the most
potent disruption of RBC engagement is expected by targeting
DARC binding sites. Recent work examining the mechanism of
monoclonal antibodies targeting EBL ligands supports the view
that targeting receptor binding sites and multimerization interfaces
of EBL ligands effectively prevents RBC binding and limits
parasite growth in vitro [42]. Additionally, glycan masking
experiments with DBP-RII identified the dimer interface and
surfaces adjacent to this interface as critical binding sites and
targets of an inhibitory antibody response [28]. This result
supports the importance of identifying and targeting essential
functional residues/interfaces of DBP-RII and confirms the
biological importance of the contact points identified in this study.
This work also has implications for diagnostics and measures
aiming to quantify the immune response to natural infection and in
determining the efficacy of vaccine candidates. For a more robust
measure of protection, these approaches should quantify the
immune response to the functional regions identified here in
addition to the response to the entire DBP-RII DBL domain. This
study thus expands our understanding of the essential interaction
between DBP and DARC and may aid in defining in vivo studies that
seek to examine the extensive receptor-ligand binding interactions
that are essential to RBC invasion by Plasmodium species.
Materials and Methods
Protein expression, purification, and complex formation
DBP-RII and DARC were produced as previously described
[26]. DARC constructs were expressed in E. coli with an
Figure 8. A model for attachment during invasion. An initial binding event is followed by receptor-induced dimerization, as in the DBP-
RII:DARC heterotrimer. This brings a second DBP-RII molecule in close proximity to a second DARC ectodomain in the DARC homodimer. A second
binding event creates the DBP-RII:DARC heterotetramer. DBP-RII molecules are in green and yellow and DARC19–30 molecules are in purple and blue.
The DARC homodimer is represented by a homology model. A schematic for the stepwise assembly is shown at the bottom. Closed circle – bound
DBP-RII, open circle – unbound DBP-RII.
doi:10.1371/journal.ppat.1003869.g008
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N-terminal GB1 tag, followed by a hexahistidine tag and a
PreScission Protease cleavage site. Nickel-NTA chromatography
followed by PreScission protease treatment and gel filtration
resulted in a homogenous sample.
NMR
NMR data were collected at 298 K on a 600 MHz Bruker
spectrometer equipped with a triple-resonance room temperature
probe and a QCI cryoprobe. Backbone assignments for the non-
proline residues in DARC 1–60 were obtained using standard
HNCACB, CBCA(CO)NH, HN(CA)CO, and HNCO experi-
ments. Once the DARC 1–60 backbone resonances had been
assigned, we collected 1H-15N-TROSY spectra of DARC 1–60 in
the presence of DBP-RII. As DARC residues tightly bound to
DBP-RII in a large complex are not visible, peaks which remain in
the DBP-RII:DARC 2D 1H-15N TROSY and 3D TROSY triple
resonance spectra revealed residues which are not bound by DBP-
RII.
Crystallization and data collection
Before complex formation, DBP-RII and DARC were purified
separately by size-exclusion chromatography to remove any trace
aggregates in either sample. The DBP-RII:DARC complexes were
prepared by mixing purified DBP-RII and purified DARC in 1:1.2
molar ratio. The DBP-RII:DARC complexes were purified using
size-exclusion chromatography in 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4, and 50 mM
sodium chloride. These sample was then concentrated in an
Amicon concentrator with a 3-kDa molecular weight cutoff to
20 mg ml21 for crystallization trials.
Native DBP-RII:DARC crystals of both constructs were grown
by hanging-drop vapor diffusion by mixing 1 ml of protein solution
at 20 mg ml21 and 1 ml of reservoir solution containing 0.1 M
HEPES pH 7.4 and 20% (w/v) polyethylene glycol 6000.
Crystallization of DBP-RII in complex with DARC 16–43 yielded
the heterotrimeric structures, while crystallization of DBP-RII in
complex with DARC 14–43 yielded the heterotetrameric crystals.
The different crystal forms are not due to the DARC constructs
used, rather serendipitous formation of one or either of the stable
states upon complex assembly. Crystals were cryoprotected by
transfer to reservoir solutions supplemented with glycerol and flash
frozen in liquid nitrogen. Data for the heterotetramer was
collected at a wavelength of 1.0 A˚ at beamline 4.2.2 of the
Advanced Light Source, Lawrence Berkeley National Laboratory.
Data for the heterotrimer was collected at a wavelength of
0.97929 A˚ at beamline 19-ID of the Advanced Photon Source,
Argonne National Laboratory. Data reduction and processing was
performed in XDS [43]. Data collection statistics are shown in
Table 1.
Structure solution
Both structures were solved by molecular replacement using
DBP-RII apo-structure [26] leading to a starting model with
Rwork/Rfree of 37.3%/38.1% for the heterotrimer and an
Rwork/Rfree of 30.0%/30.1% for the heterotetramer. NCS
restraints were not imposed on the two copies of DBP-RII during
refinement as it was clear from electron density maps they were
not identical. Subsequent automated rebuilding in PHENIX
AutoBuild [44], manual rebuilding in COOT0.7 [45] and
refinement in PHENIX1.7.3 [44] lead to a final model with
Rwork/Rfree of 16.62%/20.47% for the heterotrimer and
18.29%/23.28% for the heterotetramer (Table 1). These low R
factors combined with the good Ramachandran plot statistics
analyzed by MolProbity [46] indicated that structure refinement
was complete. Residue distributions in the Ramachandran plot for
the heterotrimer were 98.42% allowed, 1.58% additionally
allowed and 0% disallowed. Residue distributions in the
Ramachandran plot for the heterotetramer were 95.72% allowed,
4.28% additionally allowed and 0% disallowed. The atomic
coordinates and structure factors for the structure have been
deposited in the protein data bank with accession numbers 4NUU
and 4NUV.
Isothermal titration calorimetry
DBP-RII was prepared as described above, with the addition of
an ion-exchange chromatography step prior to ITC measure-
ments. DBP-RII and DARC1–60 were exchanged into PBS to
ensure measurements were made under physiological conditions.
ITC experiments were carried out at 10uC using a VP-ITC
instrument (MicroCal). DARC1–60 at 1.3 mM was titrated into
1.4 mL of 130 mM DBP-RII. For control experiments, 1.3 mM
DARC 1–60 was titrated into 1.4 mL of PBS, and separately PBS
was titrated into 1.4 mL of 130 mM DBP-RII. Traces were
analyzed using Origin Version 5.0 (MicroCal). Stoichiometry and
binding constants were calculated by fitting the integrated data to
an independent two-site binding model after a double subtraction
of both controls from the experimental titration. Protein concen-
trations were determined by absorbance measurements under
denaturing conditions (6 M guanidinium hydrochloride, 10 mM
dithiothreitol).
Functional studies
DBP-RII with a C-terminally fused green fluorescent protein
(GFP) was cloned into plasmid pRE4 for surface expression in
mammalian cells. Single-amino-acid mutations were introduced in
DBP-RII using the QuickChange method (Stratagene). Fresh
monolayers of HEK293T cells were cultured in 3.5-cm-diameter
wells and transfected with 2 mg ml21 DNA in polyethyleneimine.
The binding assay was performed 20 h after transfection.
Anonymized human RBCs (ZenBio) were added to each well in
a 10% suspension, incubated at 37uC for 1 h, and washed three
times with PBS. Binding was quantified by counting rosettes
observed over ten fields of view at620 magnification. Transfected
HEK 293T cells with five or more attached RBCs were defined as
positive rosettes. In each experiment, three wells of HEK 293T
cells were transfected for each mutation. Cell counting was
performed using ImageJ (NIH) on randomized images. Three
fields of view from ten independent transfections (final n = 30)
were counted for each sample (wild type or mutant). Significance
was tested by a paired two-tailed Student’s t-test as the data were
normally distributed and had large sample sizes (n = 30).
Supporting Information
Figure S1 DARC residues 19–30 are contacted by DBP-RII.
DARC19–30 binds to a positively charged groove at the DBP-RII
dimer interface of both (A) the DBP-RII:DARC heterotrimer and
(B) the DBP-RII:DARC heterotetramer. Electrostatic potential is
shown from 27.5 to 7.5 kT/e with positive potential in blue and
negative potential in red. 2fo-fc electron density maps, contoured
at 1s clearly show the presence of (C) a single DARC19–30 in the
heterotrimer and both (D) DARC19-30A and (E) DARC19-30B
in the two DBP-RII binding sites of the heterotetramer. DARC
monomers are in purple and blue and DBP-RII monomers are in
green and yellow.
(TIFF)
Figure S2 Upon receptor binding, new regions of DBP-RII
become structured, while preexisting structural regions undergo no
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major conformational changes. During the transition from the
heterotrimeric to heterotetrameric complex, a change in the
overall architecture of the DBP-RII dimer is observed. In (A–C)
the DARC-bound DBP-RII heterotetramer is green and yellow,
the DARC-bound DBP-RII heterotrimer is light green and light
yellow, and unbound DBP-RII is dark green and orange.
Structural transitions in each case are designated with an arrow
as well as with the distance of the structural shift. (A) A translation
covering 12 A˚ along helix 4 defines the difference between the
heterotrimeric structure and a prior structure of DBP-RII in the
absence of receptor. (B) A translation covering 12 A˚ across helix 4
is the difference between the heterotrimeric structure and the
heterotetrameric structure. (C) A translation covering 23 A˚ along
helix 4 is the difference between the heterotetrameric structure
and DBP-RII in the absence of receptor, which defines the full
shift following binding of both DARC molecules. (D–G)
Alignments of the individual monomers of the DBP-RII:DARC
heterotetramer and unbound DBP-RII. (D) Monomer A of the
heterotetramer (green) with monomer A unbound (dark green), (E)
monomer A of the heterotetramer (green) with monomer B
(orange) unbound, (F) monomer B of the heterotetramer (yellow)
with monomer A unbound (dark green), (G) monomer B (yellow)
of the heterotetramer with monomer B unbound (orange).
(TIFF)
Figure S3 The sulfotyrosine binding site. DBP-RII molecules
are in green and yellow. The bound DARC molecule is shown in
purple. (A) Phosphate or selenate in the apo DBP-RII structure
occupy the same position as (B) DARC Y30, defining the
sulfotyrosine binding pocket.
(TIFF)
Figure S4 The DARC binding pockets are distinct from residues
previously suggested to bind DARC from mutagenesis studies.
DBP-RII monomers are in yellow and green. DARC monomers
are in purple and blue. Residues previously suggested [40] to
contact DARC are in black.
(TIFF)
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